Jon Hamilton | KUNC

Jon Hamilton

Jon Hamilton has served as a correspondent for NPR's science desk since 1998. His current beat includes neuroscience, health risks, behavior, and bioterrorism. Recent pieces include a series on the chemical perchlorate, which is turning up in California's water supply; a government effort to find out just how many autistic children there are in the U.S.; and an exploration of "neuromarketing."

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He completed a project on states that have radically changed their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a B.A. in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University where he graduated with honors, won the Baker Prize for magazine writing, and earned a Sherwood traveling fellowship.

For years, public health officials have been trying to dispel the myth that people who get a flu shot are more likely to get Alzheimer's disease.

They are not. And now there is evidence that vaccines that protect against the flu and pneumonia may actually protect people from Alzheimer's, too.

Three research institutions in Seattle have joined forces to study how Alzheimer's disease takes root in the brain.

The consortium will create a new research center at the Allen Institute for Brain Science to study tissue from brains donated by people who died with Alzheimer's.

Intensive care teams inside hospitals are rapidly altering the way they care for patients with COVID-19.

The changes range from new protective gear to new treatment protocols aimed at preventing deadly blood clots.

The coronavirus appears to be much more lethal in some countries than in others.

In Italy, about 10% of people known to be infected have died. In Iran and Spain, the case fatality rate is higher than 7%. But in South Korea and the U.S. it's less than 1.5%. And in Germany, the figure is close to 0.5%.

So what gives?

The answer involves how many people are tested, the age of an infected population and factors such as whether the health care system is overwhelmed, scientists say.

Scientists have taken a small step toward personalizing treatment for depression.

A study of more than 300 people with major depression found that brain wave patterns predicted which ones were most likely to respond to the drug sertraline (Zoloft), a team reported Monday in the journal Nature Biotechnology.

If the approach pans out, it could offer better care for the millions of people in the U.S. with major depression.

Scientists have found a clue to how autism spectrum disorder disrupts the brain's information highways.

The problem involves cells that help keep the traffic of signals moving smoothly through brain circuits, a team reported Monday in the journal Nature Neuroscience.

The team found that in both mouse and human brains affected by autism, there's an abnormality in cells that produce a substance called myelin.

Brain organoids, often called "minibrains," have changed the way scientists study human brain development and disorders like autism.

But the cells in these organoids differ from those in an actual brain in some important ways, scientists reported Wednesday in the journal Nature.

In early December at the Kennedy Space Center in Florida, two anxious scientists were about to send 20 years of research into orbit.

"I feel like our heart and soul is going up in that thing," Dr. Emily Germain-Lee told her husband, Dr. Se-Jin Lee, as they waited arm-in-arm for a SpaceX rocket to launch.

Black and Hispanic Americans are especially vulnerable to Alzheimer's disease. Yet they're often underrepresented in scientific studies of the disease.

So on a cool Sunday morning in Cleveland, two research associates from Case Western Reserve University's School of Medicine have set up an information table at a fundraising walk organized by the local chapter of the Alzheimer's Association.

"We are looking for families, minorities and people with early onset," Leah Cummings tells passersby who are waiting for the walk to begin.

A leukemia drug may have cleared another hurdle as a potential treatment for Parkinson's disease.

But critics say it's still not clear whether the drug, nilotinib (brand name Tasigna), is truly safe or effective for this use.

Pages